Alzheimer s & Dementia Translational Research & Clinical Interventions · 2015 · 57 citations · 23 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyNeuropharmacologyPharmacodynamicsAge-related PharmacokineticsDementia PharmacotherapyDrug DispositionNeurodegenerative Disease PharmacologyNeurodegenerative Disease PharmacotherapyPharmacokinetics In DementiaAlzheimer's Disease PharmacokineticsCerebrospinal Fluid SystemFirst-in-human Dose EscalationFraction Unbound DrugPharmacokinetics In Neurodegenerative DiseasePharmacological Treatment Of DementiaSubjectsUnbound Drug Distribution
INTRODUCTION: Pyroglutamate-amyloid-β (pE-Aβ) peptides are major components of Aβ-oligomers and Aβ-plaques, which are regarded as key culprits of Alzheimer's disease (AD) pathology. PQ912 is a competitive inhibitor of the enzyme glutaminyl cyclase (QC), essential for the formation of pE-Aβ peptides. METHODS: A randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study investigated the safety, pharmacokinetics, and pharmacodynamics of PQ912 in healthy nonelderly and elderly subjects. RESULTS: PQ912 was considered safe and well tolerated with dose-proportional pharmacokinetics up to doses of 200 mg. At higher doses up to 1800 mg, exposure was supraproportional and exposure in elderly subjects was approximately 1.5- to 2.1-fold higher. Exposure in cerebrospinal fluid (CSF) was approximately 20% of the unbound drug in plasma, and both serum and CSF QC activity was inhibited in a dose-related manner. DISCUSSION: This first-in-man study of a compound-targeting QC inhibition justifies further development of PQ912 for the treatment of AD.
23
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β
Justin Nussbaum, Stephan Schilling, Holger Cynis et al. · Nature · 2012 · 429 citations · Full text
Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in down Syndrome
Takeshi Iwatsubo, David M. A. Mann, Asano Odaka et al. · Annals of Neurology · 1995 · 385 citations